Previous studies in breast cancer highlighted that PTPRZ1 is a risk factor for poor prognosis in TNBC and found that PTN-PTPRZ1 is driven by chemotherapy, indicating its role in chemoresistance. This evidence concerns the gene PTPRZ1 and breast cancer.